How to Optimize Deimplementation of Sentinel Lymph Node Biopsy?

Overview

Journal Breast J

Publisher Wiley

Date 2025 Jan 1

PMID 39742356

Authors

Ida Dragvoll

Anna M Bofin

Havard Soiland

Monica Jernberg Engstrom

Affiliations

Soon will be listed here.

Abstract

Background: The omission of sentinel lymph node biopsy in low-risk elderly breast cancer patients has been introduced in several guidelines. Despite evidence to support its safety, this recommendation has not been implemented by many clinicians. We have examined two aspects of this recommendation that may explain why sentinel lymph node biopsy continues to be performed in most of these patients. Firstly, we quantified the proportion of patients diagnosed with axillary metastases postoperatively. Secondly, we examined adherence to antihormonal therapy in the same group of patients.

Methods: In this single-centre retrospective cohort study, the study population comprised 98 patients with breast cancer. Patients were aged ≥70 years and diagnosed with hormone receptor positive breast cancers less than 20 mm (T1). All patients underwent surgery and were subsequently prescribed five years of adjuvant antihormonal treatment.

Results: Axillary lymph node metastases, as confirmed by the postoperative histology report, were seen in 36.3%. Nonadherence was seen in 33.7% of the patients. Primary nonadherence, that is, patients that never collect their first or subsequent prescriptions at the pharmacy, comprised 11.2% of the total study population.

Conclusion: The high proportion of axillary metastases demonstrated suggests that clinical examination of the axilla alone is not sufficient in the preoperative assessment of the axilla. The less-than-optimal adherence rates show that adherence in these patients cannot be taken for granted. We suggest that these factors reflect some of the reluctance among clinicians to omit the sentinel lymph node procedure in these patients.

References

Giuliano A, Ballman K, McCall L, Beitsch P, Brennan M, Kelemen P . Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017; 318(10):918-926. PMC: 5672806. DOI: 10.1001/jama.2017.11470. View

Smaje A, Weston-Clark M, Raj R, Orlu M, Davis D, Rawle M . Factors associated with medication adherence in older patients: A systematic review. Aging Med (Milton). 2019; 1(3):254-266. PMC: 6692164. DOI: 10.1002/agm2.12045. View

Dominici L, Sineshaw H, Jemal A, Lin C, King T, Freedman R . Patterns of axillary evaluation in older patients with breast cancer and associations with adjuvant therapy receipt. Breast Cancer Res Treat. 2017; 167(2):555-566. DOI: 10.1007/s10549-017-4528-6. View

Wells K, Pan T, Vazquez-Otero C, Ung D, Ustjanauskas A, Munoz D . Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study. Support Care Cancer. 2016; 24(10):4123-30. PMC: 4995114. DOI: 10.1007/s00520-016-3229-8. View

Moynihan R, Doust J, Henry D . Preventing overdiagnosis: how to stop harming the healthy. BMJ. 2012; 344:e3502. DOI: 10.1136/bmj.e3502. View

Pak L, Morrow M . Addressing the problem of overtreatment in breast cancer. Expert Rev Anticancer Ther. 2022; 22(5):535-548. PMC: 9448354. DOI: 10.1080/14737140.2022.2064277. View

Montori V, Ruissen M, Hargraves I, Brito J, Kunneman M . Shared decision-making as a method of care. BMJ Evid Based Med. 2022; 28(4):213-217. PMC: 10423463. DOI: 10.1136/bmjebm-2022-112068. View

Chagpar A, Hatzis C, Pusztai L, DiGiovanna M, Moran M, Mougalian S . Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer. Ann Surg Oncol. 2017; 24(10):3073-3081. DOI: 10.1245/s10434-017-5936-x. View

Hughes K, Schnaper L, Berry D, Cirrincione C, McCormick B, Shank B . Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004; 351(10):971-7. DOI: 10.1056/NEJMoa040587. View

10.

Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S . Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378(9793):771-84. PMC: 3163848. DOI: 10.1016/S0140-6736(11)60993-8. View

11.

Banning M . Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review. Eur J Cancer Care (Engl). 2011; 21(1):10-9. DOI: 10.1111/j.1365-2354.2011.01295.x. View

12.

Guth U, Huang D, Schotzau A, Zanetti-Dallenbach R, Holzgreve W, Bitzer J . Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. Br J Cancer. 2008; 99(3):428-33. PMC: 2527804. DOI: 10.1038/sj.bjc.6604525. View

13.

McCowan C, Wang S, Thompson A, Makubate B, Petrie D . The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. Br J Cancer. 2013; 109(5):1172-80. PMC: 3778308. DOI: 10.1038/bjc.2013.464. View

14.

Smith M, Vitous C, Hughes T, Shubeck S, Jagsi R, Dossett L . Barriers and Facilitators to De-Implementation of the Choosing Wisely Guidelines for Low-Value Breast Cancer Surgery. Ann Surg Oncol. 2020; 27(8):2653-2663. PMC: 7338259. DOI: 10.1245/s10434-020-08285-0. View

15.

Gast A, Mathes T . Medication adherence influencing factors-an (updated) overview of systematic reviews. Syst Rev. 2019; 8(1):112. PMC: 6511120. DOI: 10.1186/s13643-019-1014-8. View

16.

Voogd A, Coebergh J, van Driel O, Roumen R, van Beek M, Vreugdenhil A . The risk of nodal metastases in breast cancer patients with clinically negative lymph nodes: a population-based analysis. Breast Cancer Res Treat. 2000; 62(1):63-9. DOI: 10.1023/a:1006447825160. View

17.

Canavese G, Catturich A, Vecchio C, Tomei D, Gipponi M, Villa G . Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann Oncol. 2009; 20(6):1001-7. DOI: 10.1093/annonc/mdn746. View

18.

Rezvani A, Zahergivar A, Iranpour P, Akrami M, Kazemi S . Diagnostic Accuracy of Axillary Ultrasonography Compared with Intra-operative Pathological Findings in Patients with Breast Cancer. Asian Pac J Cancer Prev. 2018; 19(12):3615-3621. PMC: 6428527. DOI: 10.31557/APJCP.2018.19.12.3615. View

19.

Grimshaw J, Patey A, Kirkham K, Hall A, Dowling S, Rodondi N . De-implementing wisely: developing the evidence base to reduce low-value care. BMJ Qual Saf. 2020; 29(5):409-417. PMC: 7229903. DOI: 10.1136/bmjqs-2019-010060. View

20.

Kunkler I, Williams L, Jack W, Cameron D, Dixon J . Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015; 16(3):266-73. DOI: 10.1016/S1470-2045(14)71221-5. View